Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. That said, here are three profitable companies to avoid and some better opportunities instead.
Boyd Gaming (BYD)
Trailing 12-Month GAAP Operating Margin: 17.4%
Run by the Boyd family, Boyd Gaming (NYSE: BYD) is a diversified operator of gaming entertainment properties across the United States, offering casino games, hotel accommodations, and dining.
Why Do We Steer Clear of BYD?
- Lackluster 12.7% annual revenue growth over the last five years indicates the company is losing ground to competitors
- Poor free cash flow margin of 11.1% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Boyd Gaming is trading at $84.25 per share, or 11.6x forward P/E. To fully understand why you should be careful with BYD, check out our full research report (it’s free).
Northrop Grumman (NOC)
Trailing 12-Month GAAP Operating Margin: 11.6%
Responsible for the development of the first stealth bomber, Northrop Grumman (NYSE: NOC) specializes in providing aerospace, defense, and security solutions for various industry applications.
Why Should You Dump NOC?
- Annual sales growth of 2.6% over the last five years lagged behind its industrials peers as its large revenue base made it difficult to generate incremental demand
- Estimated sales growth of 5.3% for the next 12 months is soft and implies weaker demand
- Earnings growth over the last five years fell short of the peer group average as its EPS only increased by 3.1% annually
At $589.33 per share, Northrop Grumman trades at 20.8x forward P/E. If you’re considering NOC for your portfolio, see our FREE research report to learn more.
Biogen (BIIB)
Trailing 12-Month GAAP Operating Margin: 18.8%
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ: BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Why Does BIIB Give Us Pause?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 6% annually over the last five years
- Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable
- Diminishing returns on capital suggest its earlier profit pools are drying up
Biogen’s stock price of $187.83 implies a valuation ratio of 12.2x forward P/E. Check out our free in-depth research report to learn more about why BIIB doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
